A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

作者：Andrew W. Hahn, Jad Chahoud, William Paul Skelton, Ying Yuan, Amado J. Zurita, C. Kovitz, Omar Alhalabi, Matthew T. Campbell, Eric Jonasch, John K. Lin, Meera Desai, Michael Keith San Diego. Santos, Hyunsoo Hwang, Paul G. Corn, Pavlos Msaouel, Nizar M. Tannir · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.10.009 · 被引用次数：9 · 研究领域：Renal cell carcinoma treatment、Cancer Immunotherapy and Biomarkers、Bladder and Urothelial Cancer Treatments